Financing channel feed – Endpoints News

Financing channel feed

Liver-focused startup nabs $115M in exchange for rare disease drug royalties

3 years ago

They’re going for it: David Liu’s preclinical biotech shoots for a (maybe $200M) IPO

3 years ago

Precision oncology biotech agrees to $72M cash infusion as it seeks to increase revenue

3 years ago

AbbVie expands manufacturing presence in Ireland with a €60M investment

3 years ago

Weight loss player gets attention of RA Capital, walks away with $132M to keep pursuing big targets

3 years ago

From clinical fail to raising cash? Virios goes for public offering as shares reach all-time low

3 years ago

TCR upstart gets fresh funding as it looks to charge toward the clinic

3 years ago

Following program cuts and amid drug launch, Roivant lines up $1B shelf registration

3 years ago

One SPAC's journey to find a partner, and its race against the clock, shows toughness of bear market

3 years ago

Ventyx seeks to rack up $176M+ in its latest move as the market become bullish on TYK2

3 years ago

With hit-and-miss data, Allakos goes the public offering route in $150M ask

3 years ago

The virus shredder: A Princeton spinout advised by a high-profile VC launches a Cas13 viral defense system

3 years ago

From three companies to one — Galvanize Therapeutics gets $100M to push electric field therapy

3 years ago

First of more? Third Harmonic prices upsized IPO to raise $185M

3 years ago

Genentech-partnered Novome lands $43.5M to push gastrointestinal drug through mid-stage study

3 years ago

With positive PhII NASH data in tow, Akero opens $175M public offering

3 years ago

Takeda’s manufacturing site in Belgium gets a €300M boost for plasma therapy production

3 years ago

A $105M SPAC deal? Really? A biotech with deep China roots is making a now-rare flip onto Nasdaq

3 years ago

Backed by five pharma giants and a crew of Penn superstars, a startup uses mRNA to create in vivo CAR-T — with a pro at the helm

3 years ago

‘Difficult to go public with’: SparingVision turns to existing backers to fund its first two ocular gene therapy trials

3 years ago

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

3 years ago

Forge Biologics continues its hot streak with $90M round to boost gene therapy manufacturing services

3 years ago

Acelyrin tops its $250M crossover with new $300M cash raise from blue-chip syndicate

3 years ago

Eyeing accelerated approval for Duchenne gene therapy, Sarepta hopes to bring in $1B in bid for profitability

3 years ago

First page Previous page 47 48 495051 52 53 Next page Last page